Coherus Oncology Inc（CHRS）资讯与事件CHRSCoherus Oncology Inc

Q2 Revenue at $14.31M, Below Consensus

Reports Q2 revenue $14.31M, consensus $20.44M. "During the second quarter we continued to pursue our science-driven clinical development strategy, creating multiple avenues for long-term value creation, and look forward to further maturation of data with both tagmokitug and casdozokitug," said Denny Lanfear, Chairman and Chief Executive Officer.

Coherus and Zumutor Collaborate on ZM008 Clinical Trial

Coherus Oncology and Zumutor Biologics announced a clinical collaboration and supply agreement to conduct a Phase 1 trial of ZM008, a NK checkpoint anti-LLT1 monoclonal antibody in combination with Loqtorzi, a PD-1 inhibitor. The study will enroll patients with colorectal, head and neck, non-small cell lung cancer, clear cell renal cell carcinoma and urothelial cancers, among other solid tumors. Under the terms of the greement, Coherus will provide Loqtorzi to Zumutor, which will be the sponsor of the Phase 1 clinical combination trial. Zumutor and Coherus each retain all commercial rights to their respective compounds, as monotherapies or combination therapies.

Coherus Reports Q1 Revenue of $12.31M

Reports Q1 revenue $12.31M, consensus $14.34M. "We are executing well on our integrated financial, commercial and development strategy that maximizes LOQTORZI's potential in NPC and in combination with our pipeline products." said Denny Lanfear, Coherus Chairman and Chief Executive Officer. "We also continue to explore opportunities across cancers and non-proprietary novel combinations with tagmokitug, our potentially best-in-class CCR8 Treg depleter, and are encouraged given our previously reported clinical data including anti-tumor activity, safety data, tumor biomarker data and PK data."